CD147 Plasma Levels in Hospitalised Patients with Covid-19 Pneumonia Predict Illness Severity and In-Hospital Mortality.
Stem Cell Rev Rep
; 20(2): 568-572, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-38038852
ABSTRACT
COVID-19 and infectious diseases have been included in strategic development goals (SDG) of United Nations (UN). The CD147 receptor is one of several receptors for the SARS-CoV-2 spike protein that could mediate Covid-19 viral infection of host cells. It has been recently proposed to regulate viral invasion and dissemination among lymphocytes and progenitor/stem cells. A soluble by-product of CD147 (sCD147) exists in plasma and has been previously identified as a marker of diabetes and platelet activation. We examined plasma sCD147 levels in 161 Covid-19 patients at hospital admission. We demonstrated significantly higher plasma sCD147 levels in Covid-19 patients, which correlated with plasma multiorgan dysfunction biomarkers interleukin-6, creatinine and Troponin I. Importantly, sCD147 admission levels were associated with Covid-19 severity and survival, carrying potential value as a biomarker in hospitalized patients with Covid-19 infection.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Glicoproteína da Espícula de Coronavírus
/
COVID-19
Limite:
Humans
Idioma:
En
Revista:
Stem Cell Rev Rep
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
França